Back to Top


February 11, 2015; Posted by: WeBleed staff

Baxter presents data on Phase III study of BAX 855.

MarketWatch reported today via a release from PRNewswire that the new extended factor for hemophiliacs from Baxter International, Inc. presented positive results from a resent meeting. BAX 855, an extended half-life factor VIII (8) drug, was presented at the 8th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Helsinki, Finland with additional efficacy and safety data from the Phase III pivotal study.

“These pivotal trial results provide evidence to support the efficacy profile of BAX 855 in controlling, preventing or reducing the frequency of bleeding episodes when administered prophylactically twice weekly. Our goal with BAX 855 is to extend the interval between infusions while maintaining a similar efficacy profile to ADVATE,” said John Orloff, M.D., vice president and global head of research and development for Baxter BioScience.

No patients developed inhibitors to BAX 855 during the longevity of the study.

WeBleed will post updates as more information becomes available.

Photo Credit РBaxter International, Inc. – your source for bleeding news!

Comment Here

Your email address will not be published.


Translate »